291 related articles for article (PubMed ID: 27496310)
1. Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.
Younes A; Ansell SM
Semin Hematol; 2016 Jul; 53(3):186-9. PubMed ID: 27496310
[TBL] [Abstract][Full Text] [Related]
2. Novel agents in the therapy of Hodgkin lymphoma.
Ansell S
Am Soc Clin Oncol Educ Book; 2015; ():e479-82. PubMed ID: 25993212
[TBL] [Abstract][Full Text] [Related]
3. Novel agents for the treatment of Hodgkin lymphoma.
Dumaswala K; Mehta A
Expert Rev Hematol; 2015 Oct; 8(5):659-67. PubMed ID: 26343891
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
Alperovich A; Younes A
Cancer J; 2016; 22(1):23-6. PubMed ID: 26841013
[TBL] [Abstract][Full Text] [Related]
5. [Hodgkin Lymphoma].
Ghesquières H
Rev Prat; 2017 Mar; 67(3):313-320. PubMed ID: 30657300
[TBL] [Abstract][Full Text] [Related]
6. Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.
Carlo-Stella C; Santoro A
Biomark Med; 2015; 9(8):807-17. PubMed ID: 26223461
[TBL] [Abstract][Full Text] [Related]
7. Standard therapies versus novel therapies in Hodgkin lymphoma.
Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
[TBL] [Abstract][Full Text] [Related]
8. Targeting Immune System Alterations in Hodgkin Lymphoma.
Grover NS; Savoldo B
Curr Hematol Malig Rep; 2017 Aug; 12(4):358-369. PubMed ID: 28780614
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic agents for relapsed classical Hodgkin lymphoma.
von Keudell G; Younes A
Br J Haematol; 2019 Jan; 184(1):105-112. PubMed ID: 30536386
[TBL] [Abstract][Full Text] [Related]
10. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
11. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for the treatment of Hodgkin lymphoma.
Donato EM; Fernández-Zarzoso M; De La Rubia J
Expert Rev Hematol; 2017 May; 10(5):417-423. PubMed ID: 28359170
[TBL] [Abstract][Full Text] [Related]
13. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
[TBL] [Abstract][Full Text] [Related]
14. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
[TBL] [Abstract][Full Text] [Related]
15. CD30 as a therapeutic target for lymphoma.
Schirrmann T; Steinwand M; Wezler X; Ten Haaf A; Tur MK; Barth S
BioDrugs; 2014 Apr; 28(2):181-209. PubMed ID: 24043362
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy in relapsed classical hodgkin lymphoma.
Dinner S; Advani R
J Natl Compr Canc Netw; 2013 Aug; 11(8):968-76. PubMed ID: 23946175
[TBL] [Abstract][Full Text] [Related]
17. The Role of Reed-Sternberg CD30 Receptor and Lymphocytes in Pathogenesis of Disease and Its Implication for Treatment.
Rinaldi I
Acta Med Indones; 2018 Apr; 50(2):93-95. PubMed ID: 29950526
[TBL] [Abstract][Full Text] [Related]
18. The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.
Eichenauer DA; Engert A
Expert Rev Hematol; 2017 Sep; 10(9):775-782. PubMed ID: 28665214
[TBL] [Abstract][Full Text] [Related]
19. Recent treatment advances in Hodgkin lymphoma: a concise review.
Arulogun S; Hertzberg M; Gandhi MK
Intern Med J; 2016 Dec; 46(12):1364-1369. PubMed ID: 26929077
[TBL] [Abstract][Full Text] [Related]
20. [New therapy outlooks in Hodgkin lymphoma].
Rossi C; Casasnovas RO
Bull Cancer; 2017 Feb; 104(2):182-194. PubMed ID: 28088309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
